SCHEMBL481597

SCHEMBL481597

C1=CCCCC(C2CCCCCC2)=C1

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049799 1.00 MAPT (0.30) MAPT
SCHEMBL7638599 0.94
SCHEMBL7637193 0.94
SCHEMBL7640093 0.94
SCHEMBL1052042 0.94 KDM1A (0.31)
SCHEMBL7637190 0.94
SCHEMBL7640090 0.94
SCHEMBL1052040 0.94 KDM1A (0.31)
SCHEMBL6015270 0.94 KDM1A (0.31)
SCHEMBL7638595 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118215676-A Specific conjugation of antibody drug conjugates 杭州多禧生物科技有限公司 2024-06-18 CN disclosed
CN-117980327-A Specific coupling of antibodies 杭州多禧生物科技有限公司 2024-05-03 CN disclosed
CN-110023334-B anti-GP 73 antibodies and immunoconjugates 科雅博有限责任公司 2023-11-14 CN disclosed
CN-116940586-A Compounds comprising fibroblast activation protein ligands and uses thereof 3B制药有限公司 2023-10-24 CN disclosed
CN-116940585-A Compounds comprising fibroblast activation protein ligands and uses thereof 3B制药有限公司 2023-10-24 CN disclosed
CN-116143678-A Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof 杭州多禧生物科技有限公司 2023-05-23 CN disclosed
CN-116063515-A anti-FCRH 5 antibodies 基因泰克公司 2023-05-05 CN disclosed
CN-115443134-A Conjugates of cell binding molecules and camptothecin analogs 杭州多禧生物科技有限公司 2022-12-06 CN disclosed
EP-3997104-A1 COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF 3B Pharmaceuticals GmbH (DE) 2022-05-18 EP disclosed
CN-114206340-A Methods of treating follicular lymphoma using anti-CD 79B immunoconjugates 豪夫迈·罗氏有限公司 2022-03-18 CN disclosed
CN-112272669-A Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof 杭州多禧生物科技有限公司 2021-01-26 CN disclosed
WO-2021005131-A1 COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2021-01-14 WO disclosed
CN-111093707-A Tubulysin homolog conjugates containing branched linkers 杭州多禧生物科技有限公司 2020-05-01 CN disclosed
CN-110621673-A Double-stranded linked cytotoxic drug conjugates 杭州多禧生物科技有限公司 2019-12-27 CN disclosed
EP-3505191-A1 AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS Seattle Genetics, Inc. (US) 2019-07-03 EP disclosed
EP-1817336-B1 AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS SEATTLE GENETICS INC (US) 2019-01-09 EP disclosed
EP-2844300-B1 ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH INC (US) 2018-10-17 EP disclosed
EP-3046940-A1 METHODS OF USING ANTI-LGR5 ANTIBODIES F. Hoffmann-La Roche AG (CH) 2016-07-27 EP disclosed
WO-2015042108-A1 METHODS OF USING ANTI-LGR5 ANTIBODIES GENENTECH, INC. (US) 2015-03-26 WO disclosed
EP-2078016-B1 HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARM LLC (US) 2012-02-01 EP disclosed